# WHWK catalysts: Whitehawk Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/whwk/catalysts

> Whitehawk Therapeutics, Inc. (WHWK) has 4 upcoming catalysts. The next is the HWK-007 interim data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, year only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for WHWK?

Whitehawk Therapeutics, Inc. (WHWK) has 4 upcoming catalysts. The next is the HWK-007 interim data readout, 1H 2027. Press release filed with the SEC (EX-99): ""We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027," said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics." [Calendar and source filings](https://sec-api.dev/companies/whwk/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-452704, https://www.sec.gov/Archives/edgar/data/1422142/000119312526452704/whwk-ex99_1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/whwk/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Whitehawk Therapeutics, Inc. |
| Ticker | WHWK (Nasdaq) |
| SEC CIK | 1422142 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/whwk |

## Cash runway

Cash $169.7M as of 2026-09-30; quarterly burn $19.7M; about 25.9 months of runway at that rate (XBRL company facts, accession 0001193125-26-453576).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 30, 2024 | [SirolimusEFR (sirolimus) FDA approval](https://sec-api.dev/pdufa/sirolimus) | WHWK |  | completed, approved | "FYARRO is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa), with cumulative revenue of $25.2 million reported over the prior four quarters ended September 30, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312524282407/d891246dex991.htm)) |
| March 18, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312525056708/d839636dex991.htm)) |
| May 8, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000162828025023788/aadi-20250508xex991.htm)) |
| August 7, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000095017025104592/whwk-ex99_1.htm)) |
| November 6, 2025 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312525268134/whwk-ex99_1.htm)) |
| 2026 | [HWK-016 trial start](https://sec-api.dev/pdufa/hwk-016) | WHWK |  | scheduled | "Subject to FDA acceptance, we plan to initiate Phase 1 trial in ovarian cancer in 2026, with the potential to expand into other cancers affecting women, such as endometrial and cervical cancer, where we believe HWK-016 can make a meaningful impact." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1422142/000162828025015269/aadi-20241231.htm)) |
| March 12, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/whwk-ex99_1.htm)) |
| May 7, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/whwk-ex99_1.htm)) |
| August 6, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526337069/whwk-ex99_1.htm)) |
| November 9, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526452704/whwk-ex99_1.htm)) |
| 1H 2027 | [HWK-007 interim data readout](https://sec-api.dev/pdufa/hwk-007) | WHWK |  | scheduled | ""We continue to dose escalate patients in our Phase 1 programs for HWK-007 and HWK-016 and remain on track to report initial data in the first half of 2027," said Dave Lennon, PhD, President and Chief Executive Officer of Whitehawk Therapeutics." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526452704/whwk-ex99_1.htm)) |
| 1H 2027 | [HWK-007 topline data readout](https://sec-api.dev/pdufa/hwk-007) | WHWK |  | scheduled | "We expect data readout in the first half of 2027 from the Phase 1 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422142/000119312526212075/whwk-20260331.htm)) |
| 1H 2027 | [HWK-016 topline data readout](https://sec-api.dev/pdufa/hwk-016) | WHWK |  | scheduled | "We expect data readout in the first half of 2027 from the Phase 1 trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422142/000119312526212075/whwk-20260331.htm)) |
| late 2027 | [HWK-206 interim data readout](https://sec-api.dev/pdufa/hwk-206) | WHWK |  | scheduled | "We expect initial data readout for the HWK-206 Phase 1 clinical trial by year-end 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1422142/000119312526453576/whwk-20260930.htm)) |

## Drugs

- [HWK-007](https://sec-api.dev/pdufa/hwk-007): 
- [HWK-016](https://sec-api.dev/pdufa/hwk-016): 
- [HWK-206](https://sec-api.dev/pdufa/hwk-206): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/whwk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "WHWK catalysts: Whitehawk Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/whwk/catalysts

```bibtex
@misc{secapidev_companies_whwk_catalysts_20261116,
  title        = {WHWK catalysts: Whitehawk Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/whwk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_whwk_catalysts_20261116","title":"WHWK catalysts: Whitehawk Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/whwk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
